The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis

Chapter

Abstract

Pancreatic ductal adenocarcinoma is a deadly tumor. Despite several advances in conventional and targeted therapies over decades, its mortality remains slightly less than its frequency. One of its main features is its compact stroma which is formed by pancreatic stellate cells. In the last decade, it became evident that the stromal component of the tumor is not a passive scaffold, but an active player in carcinogenesis. This component is mostly missing in our experimental settings. Even in genetically engineered mouse models where a fibrotic stroma is visible, tumor responses are different than in humans. Our inability to recreate the tumor microenvironment often leads to optimistic results in the therapy of pancreatic cancer. This temporary optimism is often lost after first clinical trials. Here we would summarize various approaches to treat pancreatic cancer and scrutinize their pros and cons from a biologic point of view.

Keywords

Manifold Doxorubicin Integrin Alkaloid Bevacizumab 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedGoogle Scholar
  2. 2.
    Freeny PC, Traverso LW, Ryan JA (1993) Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 165(5):600–606PubMedGoogle Scholar
  3. 3.
    Camacho D et al (2005) Value of laparoscopy in the staging of pancreatic cancer. JOP 6(6):552–561PubMedGoogle Scholar
  4. 4.
    Canto MI et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804, quiz e14-5PubMedCentralPubMedGoogle Scholar
  5. 5.
    Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273(20):1605–1609PubMedGoogle Scholar
  6. 6.
    Michaud DS et al (2001) Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 286(8):921–929PubMedGoogle Scholar
  7. 7.
    Lowenfels AB et al (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328(20):1433–1437PubMedGoogle Scholar
  8. 8.
    Giardiello FM et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453PubMedGoogle Scholar
  9. 9.
    Klein AP et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638PubMedGoogle Scholar
  10. 10.
    Scarlett CJ et al (2011) Precursor lesions in pancreatic cancer: morphological and molecular pathology. Pathology 43(3):183–200PubMedGoogle Scholar
  11. 11.
    Hruban RH, Maitra A, Goggins M (2008) Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 1(4):306–316PubMedCentralPubMedGoogle Scholar
  12. 12.
    Sipos B et al (2009) Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9(1–2):45–54PubMedGoogle Scholar
  13. 13.
    Hruban RH et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6(8):2969–2972PubMedGoogle Scholar
  14. 14.
    Remmers N et al (2010) Molecular pathology of early pancreatic cancer. Cancer Biomark 9(1–6):421–440PubMedGoogle Scholar
  15. 15.
    Guerra C et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11(3):291–302PubMedGoogle Scholar
  16. 16.
    Hingorani SR et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6):437–450PubMedGoogle Scholar
  17. 17.
    van Heek NT et al (2002) Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161(5):1541–1547PubMedGoogle Scholar
  18. 18.
    Luttges J et al (2001) Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 158(5):1677–1683PubMedGoogle Scholar
  19. 19.
    Wilentz RE et al (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60(7):2002–2006PubMedGoogle Scholar
  20. 20.
    Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57(11):2140–2143PubMedGoogle Scholar
  21. 21.
    Lohr M et al (2005) Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7(1):17–23PubMedCentralPubMedGoogle Scholar
  22. 22.
    Almoguera C et al (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4):549–554PubMedGoogle Scholar
  23. 23.
    Matsuda Y, Kure S, Ishiwata T (2012) Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 45(2):59–65PubMedGoogle Scholar
  24. 24.
    Fernandez-del Castillo C, Warshaw AL (2001) Cystic neoplasms of the pancreas. Pancreatology 1(6):641–647PubMedGoogle Scholar
  25. 25.
    Tseng JF et al (2005) Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg 242(3):413–419, discussion 419-21PubMedGoogle Scholar
  26. 26.
    Colonna J et al (2008) Serous cystadenoma of the pancreas: clinical and pathological features in 33 patients. Pancreatology 8(2):135–141PubMedGoogle Scholar
  27. 27.
    Ng DZ et al (2009) Cystic neoplasms of the pancreas: current diagnostic modalities and management. Ann Acad Med Singapore 38(3):251–259PubMedGoogle Scholar
  28. 28.
    Basturk O, Coban I, Adsay NV (2009) Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 133(3):423–438PubMedGoogle Scholar
  29. 29.
    Zamboni G et al (1999) Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 23(4):410–422PubMedGoogle Scholar
  30. 30.
    Thompson LD et al (1999) Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol 23(1):1–16PubMedGoogle Scholar
  31. 31.
    Goh BK et al (2006) A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg 30(12):2236–2245PubMedGoogle Scholar
  32. 32.
    Sarr MG et al (2003) Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg 7(3):417–428PubMedGoogle Scholar
  33. 33.
    Furukawa T et al (2011) Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60(4):509–516PubMedGoogle Scholar
  34. 34.
    Tanaka M et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12(3):183–197PubMedGoogle Scholar
  35. 35.
    Kloppel G, Kosmahl M (2001) Cystic lesions and neoplasms of the pancreas. The features are becoming clearer. Pancreatology 1(6):648–655PubMedGoogle Scholar
  36. 36.
    Pour P (1978) Islet cells as a component of pancreatic ductal neoplasms. I. Experimental study: ductular cells, including islet cell precursors, as primary progenitor cells of tumors. Am J Pathol 90(2):295–316PubMedGoogle Scholar
  37. 37.
    Stanger BZ et al (2005) Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185–195PubMedGoogle Scholar
  38. 38.
    Aichler M et al (2012) Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226(5):723–734PubMedGoogle Scholar
  39. 39.
    Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMedGoogle Scholar
  40. 40.
    Takao S, Ding Q, Matsubara S (2012) Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. J Hepatobiliary Pancreat Sci 19(6):614–620PubMedGoogle Scholar
  41. 41.
    Li C et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037PubMedGoogle Scholar
  42. 42.
    Hermann PC et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323PubMedGoogle Scholar
  43. 43.
    Oshima Y et al (2007) Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 132(2):720–732PubMedGoogle Scholar
  44. 44.
    Li C et al (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218–2227 e5PubMedGoogle Scholar
  45. 45.
    Olempska M et al (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6(1):92–97PubMedGoogle Scholar
  46. 46.
    Rasheed ZA et al (2010) Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102(5):340–351PubMedGoogle Scholar
  47. 47.
    Zhao M et al (2007) Evidence for the presence of stem cell-like progenitor cells in human adult pancreas. J Endocrinol 195(3):407–414PubMedGoogle Scholar
  48. 48.
    Sanada Y et al (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32(2):164–170PubMedGoogle Scholar
  49. 49.
    McCord AM et al (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7(4):489–497PubMedGoogle Scholar
  50. 50.
    Moriyama T et al (2010) Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer 116(14):3357–3368PubMedGoogle Scholar
  51. 51.
    Miyake K et al (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36(3):e1–e9PubMedGoogle Scholar
  52. 52.
    Hernandez-Munoz I et al (2008) Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8(4–5):462–469PubMedGoogle Scholar
  53. 53.
    Apte MV et al (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29(3):179–187PubMedGoogle Scholar
  54. 54.
    Bachem MG et al (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115(2):421–432PubMedGoogle Scholar
  55. 55.
    Lee HO et al (2011) FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245PubMedCentralPubMedGoogle Scholar
  56. 56.
    Esposito I et al (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57(6):630–636PubMedGoogle Scholar
  57. 57.
    de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37PubMedGoogle Scholar
  58. 58.
    Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78PubMedGoogle Scholar
  59. 59.
    Taeger J et al (2011) Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10(11):2157–2167PubMedGoogle Scholar
  60. 60.
    Sangai T et al (2005) Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer 115(6):885–892PubMedGoogle Scholar
  61. 61.
    Ceyhan GO et al (2010) Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann Surg 251(5):923–931PubMedGoogle Scholar
  62. 62.
    Zhu Z et al (2002) Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog 35(3):138–147PubMedGoogle Scholar
  63. 63.
    Erkan M et al (2007) Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132(4):1447–1464PubMedGoogle Scholar
  64. 64.
    Erkan M et al (2008) The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 6(10):1155–1161PubMedGoogle Scholar
  65. 65.
    Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1(1):46–54PubMedCentralPubMedGoogle Scholar
  66. 66.
    Lunevicius R et al (2001) Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 127(3):193–199PubMedGoogle Scholar
  67. 67.
    Erkan M et al (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9(8):454–467PubMedGoogle Scholar
  68. 68.
    Erkan M et al (2012) How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol 3:389PubMedCentralPubMedGoogle Scholar
  69. 69.
    Erkan M et al (2009) Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11(5):497–508PubMedCentralPubMedGoogle Scholar
  70. 70.
    Couvelard A et al (2005) Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 46(6):668–676PubMedGoogle Scholar
  71. 71.
    Koong AC et al (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48(4):919–922PubMedGoogle Scholar
  72. 72.
    Olive KP et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457–1461PubMedCentralPubMedGoogle Scholar
  73. 73.
    Erkan M et al (2012) The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med 12(3):288–303PubMedGoogle Scholar
  74. 74.
    Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8(1):56–61PubMedGoogle Scholar
  75. 75.
    Erkan M et al (2012) StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61(2):172–178PubMedCentralPubMedGoogle Scholar
  76. 76.
    Yen TW et al (2002) Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 131(2):129–134PubMedGoogle Scholar
  77. 77.
    Bachem MG et al (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128(4):907–921PubMedGoogle Scholar
  78. 78.
    Masamune A, Shimosegawa T (2009) Signal transduction in pancreatic stellate cells. J Gastroenterol 44(4):249–260PubMedGoogle Scholar
  79. 79.
    Kim N et al (2009) Formation of vitamin A lipid droplets in pancreatic stellate cells requires albumin. Gut 58(10):1382–1390PubMedGoogle Scholar
  80. 80.
    Berna MJ et al (2010) CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem 285(50):38905–38914PubMedGoogle Scholar
  81. 81.
    Armstrong T et al (2004) Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 10(21):7427–7437PubMedGoogle Scholar
  82. 82.
    Schmid-Kotsas A et al (1999) Lipopolysaccharide-activated macrophages stimulate the synthesis of collagen type I and C-fibronectin in cultured pancreatic stellate cells. Am J Pathol 155(5):1749–1758PubMedGoogle Scholar
  83. 83.
    Masamune A et al (2009) Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58(4):550–559PubMedGoogle Scholar
  84. 84.
    Apte MV et al (1999) Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 44(4):534–541PubMedGoogle Scholar
  85. 85.
    Miyamoto H et al (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28(1):38–44PubMedGoogle Scholar
  86. 86.
    Phillips PA et al (2003) Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut 52(2):275–282PubMedGoogle Scholar
  87. 87.
    Corcoran ML et al (1996) MMP-2: expression, activation and inhibition. Enzyme Protein 49(1–3):7–19PubMedGoogle Scholar
  88. 88.
    Liu J et al (2012) BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front Biosci 17:2541–2549Google Scholar
  89. 89.
    Soubani O et al (2012) Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 33(8):1563–1571PubMedGoogle Scholar
  90. 90.
    Fujisawa T et al (2012) Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS One 7(4):e34437PubMedCentralPubMedGoogle Scholar
  91. 91.
    Binker MG et al (2010) Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/MMP-2. Biochem Biophys Res Commun 393(3):371–376PubMedGoogle Scholar
  92. 92.
    Bloomston M et al (2005) TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg 189(6):675–679PubMedGoogle Scholar
  93. 93.
    Jones LE et al (2004) Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10(8):2832–2845PubMedGoogle Scholar
  94. 94.
    Michalski CW et al (2007) Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. J Transl Med 5:63PubMedCentralPubMedGoogle Scholar
  95. 95.
    Tian M et al (2008) Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8:241PubMedCentralPubMedGoogle Scholar
  96. 96.
    Durlik M, Gardian K (2012) Metalloproteinase 2 and 9 activity in the development of pancreatic cancer. Pol Przegl Chir 84(8):377–382PubMedGoogle Scholar
  97. 97.
    Zhang Y, Ma B, Fan Q (2010) Mechanisms of breast cancer bone metastasis. Cancer Lett 292(1):1–7PubMedGoogle Scholar
  98. 98.
    Yuan S et al (1996) Transdifferentiation of human islets to pancreatic ductal cells in collagen matrix culture. Differentiation 61(1):67–75PubMedGoogle Scholar
  99. 99.
    Ingber DE, Madri JA, Jamieson JD (1981) Role of basal lamina in neoplastic disorganization of tissue architecture. Proc Natl Acad Sci USA 78(6):3901–3905PubMedGoogle Scholar
  100. 100.
    Lai Wing Sun K, Correia JP, Kennedy TE (2011) Netrins: versatile extracellular cues with diverse functions. Development 138(11):2153–2169PubMedGoogle Scholar
  101. 101.
    Ryschich E et al (2009) Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer. Pancreas 38(7):804–810PubMedGoogle Scholar
  102. 102.
    Schwarz RE et al (2010) Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther 9(8):632–639PubMedGoogle Scholar
  103. 103.
    Paron I et al (2011) Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 6(6):e21684PubMedCentralPubMedGoogle Scholar
  104. 104.
    van der Zee JA et al (2012) Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer. Br J Cancer 107(7):1153–1158PubMedCentralPubMedGoogle Scholar
  105. 105.
    Huanwen W et al (2009) Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8:125PubMedCentralPubMedGoogle Scholar
  106. 106.
    Kanemaru M et al (2012) Thrombin stimulates integrin beta1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1. Hepatogastroenterology 59(117):1614–1620PubMedGoogle Scholar
  107. 107.
    Aprile G et al (2013) Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol 34(1):131–137PubMedGoogle Scholar
  108. 108.
    Collins AL et al (2012) Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 19(8):2673–2678PubMedCentralPubMedGoogle Scholar
  109. 109.
    Kalra MK et al (2003) State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 76(912):857–865PubMedGoogle Scholar
  110. 110.
    Kim SJ et al (2012) Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability. Oncogene. 2012 Aug 20. doi: 10.1038/onc.2012.366. [Epub ahead of print]Google Scholar
  111. 111.
    Kuehn R et al (1999) Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 18(1):96–103PubMedGoogle Scholar
  112. 112.
    Meadows KN, Bryant P, Pumiglia K (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276(52):49289–49298PubMedGoogle Scholar
  113. 113.
    Blancher C et al (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61(19):7349–7355PubMedGoogle Scholar
  114. 114.
    Yu JL et al (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295(5559):1526–1528PubMedGoogle Scholar
  115. 115.
    Shi Q et al (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61(10):4143–4154PubMedGoogle Scholar
  116. 116.
    Farrow B, Evers BM (2002) Inflammation and the development of pancreatic cancer. Surg Oncol 10(4):153–169PubMedGoogle Scholar
  117. 117.
    Wong YC, Wang YZ (2000) Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol 199:65–116PubMedGoogle Scholar
  118. 118.
    Tjomsland V et al (2011) The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol 2011:212810PubMedCentralPubMedGoogle Scholar
  119. 119.
    Aoyagi Y et al (2004) Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br J Cancer 91(7):1316–1326PubMedCentralPubMedGoogle Scholar
  120. 120.
    Ozaki H et al (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29(1):16–22PubMedGoogle Scholar
  121. 121.
    Kayahara M et al (1995) Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 117(6):616–623PubMedGoogle Scholar
  122. 122.
    Kayahara M et al (1993) An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72(7):2118–2123PubMedGoogle Scholar
  123. 123.
    Kayahara M et al (1991) Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 10(2):105–111PubMedGoogle Scholar
  124. 124.
    Demir IE, Friess H, Ceyhan GO (2012) Nerve-cancer interactions in the stromal biology of pancreatic cancer. Front Physiol 3:97PubMedCentralPubMedGoogle Scholar
  125. 125.
    Zhu Z et al (1999) Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 17(8):2419–2428PubMedGoogle Scholar
  126. 126.
    Hirai I et al (2002) Perineural invasion in pancreatic cancer. Pancreas 24(1):15–25PubMedGoogle Scholar
  127. 127.
    Zhu ZW et al (2001) Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res 7(1):105–112PubMedGoogle Scholar
  128. 128.
    Liu B, Lu KY (2002) Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1(3):469–476PubMedGoogle Scholar
  129. 129.
    Ceyhan GO et al (2009) Pancreatic neuropathy and neuropathic pain–a comprehensive pathomorphological study of 546 cases. Gastroenterology 136(1):177–186 e1PubMedGoogle Scholar
  130. 130.
    Bapat AA et al (2011) Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 11(10):695–707PubMedGoogle Scholar
  131. 131.
    Samkharadze T et al (2011) Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am J Gastroenterol 106(5):968–980PubMedGoogle Scholar
  132. 132.
    Demir IE et al (2010) The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity. Neurogastroenterol Motil 22(4):480–490, e112-3PubMedGoogle Scholar
  133. 133.
    Haas SL et al (2009) Transforming growth factor-beta induces nerve growth factor expression in pancreatic stellate cells by activation of the ALK-5 pathway. Growth Factors 27(5):289–299PubMedGoogle Scholar
  134. 134.
    Philip PA et al (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27(33):5660–5669PubMedGoogle Scholar
  135. 135.
    Ying JE, Zhu LM, Liu BX (2012) Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18(8):736–745PubMedGoogle Scholar
  136. 136.
    Fukasawa M, Korc M (2004) Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10(10):3327–3332PubMedGoogle Scholar
  137. 137.
    Joensson P et al (2011) A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbecks Arch Surg 396(4):535–541PubMedGoogle Scholar
  138. 138.
    Wicki A et al (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 18(2):454–464PubMedGoogle Scholar
  139. 139.
    Kindler HL et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22):3617–3622PubMedGoogle Scholar
  140. 140.
    Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966PubMedGoogle Scholar
  141. 141.
    Safran H et al (2001) Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24(5):496–499PubMedGoogle Scholar
  142. 142.
    Komoto M et al (2009) HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100(7):1243–1247PubMedGoogle Scholar
  143. 143.
    Safran H et al (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22(5):706–712PubMedGoogle Scholar
  144. 144.
    Philip PA et al (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28(22):3605–3610PubMedGoogle Scholar
  145. 145.
    Merchan JR et al (2012) Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol 35(5):446–450PubMedGoogle Scholar
  146. 146.
    Zhou GX et al (2004) Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer. World J Gastroenterol 10(9):1337–1340PubMedGoogle Scholar
  147. 147.
    Appels NM, Beijnen JH, Schellens JH (2005) Development of farnesyl transferase inhibitors: a review. Oncologist 10(8):565–578PubMedGoogle Scholar
  148. 148.
    Matsui Y et al (2003) Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor. Oncol Rep 10(5):1525–1528PubMedGoogle Scholar
  149. 149.
    Macdonald JS et al (2005) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 23(5):485–487PubMedGoogle Scholar
  150. 150.
    Kullmann F et al (2011) KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 81(1):3–8PubMedGoogle Scholar
  151. 151.
    Hotary KB et al (2003) Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114(1):33–45PubMedGoogle Scholar
  152. 152.
    Awla D et al (2012) Neutrophil-derived matrix metalloproteinase-9 is a potent activator of trypsinogen in acinar cells in acute pancreatitis. J Leukoc Biol 91(5):711–719PubMedGoogle Scholar
  153. 153.
    Ellenrieder V et al (2000) Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 85(1):14–20PubMedGoogle Scholar
  154. 154.
    Bramhall SR et al (1997) Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182(3):347–355PubMedGoogle Scholar
  155. 155.
    Iacobuzio-Donahue CA et al (2002) Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 160(1):91–99PubMedGoogle Scholar
  156. 156.
    Krantz SB et al (2011) MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. Mol Cancer Res 9(10):1294–1304PubMedCentralPubMedGoogle Scholar
  157. 157.
    Kapischke M et al (2008) Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo. Int J Oncol 32(1):273–282PubMedGoogle Scholar
  158. 158.
    Funel N et al (2010) Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 10(5):545–552PubMedGoogle Scholar
  159. 159.
    Gansauge F et al (2007) The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterology 54(75):917–920PubMedGoogle Scholar
  160. 160.
    Conroy T, Gavoille C, Adenis A (2011) Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 23(4):390–395PubMedGoogle Scholar
  161. 161.
    Fingleton B (2008) MMPs as therapeutic targets–still a viable option? Semin Cell Dev Biol 19(1):61–68PubMedCentralPubMedGoogle Scholar
  162. 162.
    Bissell MJ, Hines WC (2011) Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320–329PubMedCentralPubMedGoogle Scholar
  163. 163.
    Winter JM et al (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 19(1):169–175PubMedGoogle Scholar
  164. 164.
    Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825PubMedGoogle Scholar
  165. 165.
    Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67PubMedCentralPubMedGoogle Scholar
  166. 166.
    Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6(3):227–239PubMedGoogle Scholar
  167. 167.
    Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231PubMedCentralPubMedGoogle Scholar
  168. 168.
    Perez-Mancera PA et al (2012) What we have learned about pancreatic cancer from mouse models. Gastroenterology 142(5):1079–1092PubMedGoogle Scholar
  169. 169.
    Folkman J et al (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219):58–61PubMedGoogle Scholar
  170. 170.
    Xie L et al (2011) Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci USA 108(24):9939–9944PubMedGoogle Scholar
  171. 171.
    Jacobetz MA et al (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1):112–120PubMedCentralPubMedGoogle Scholar
  172. 172.
    Provenzano PP et al (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418–429PubMedCentralPubMedGoogle Scholar
  173. 173.
    Erkan M (2013) The role of pancreatic stellate cells in pancreatic cancer. Pancreatology: official journal of the International Association of Pancreatology 13(2):106–109Google Scholar
  174. 174.
    Filippou DK et al (2004) Modified capitonage in partial cystectomy performed for liver hydatid disease: report of 2 cases. BMC Surg 4:8PubMedCentralPubMedGoogle Scholar
  175. 175.
    Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28(2 Suppl 8):36–41PubMedGoogle Scholar
  176. 176.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedGoogle Scholar
  177. 177.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedGoogle Scholar
  178. 178.
    Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418(6900):823PubMedGoogle Scholar
  179. 179.
    Gillies RJ, Verduzco D, Gatenby RA (2012) Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12(7):487–493PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Surgery, Klinikum rechts der IsarTechnische Universität MünchenMunichGermany

Personalised recommendations